Some features may not work as expected in this browser. For the full NewsNow experience, please consider updating your browser or trying a different device. Some features may not work as expected.
Please consider updating your browser or device.

Home
Hot Topics
US
Politics
World
Sports
Business
Crypto
Entertainment
Lifestyle
AI
Tech
Science

"ESMO 2026"
Topics

Advertisement

Advertisement

"ESMO 2026"

Showing articles that match "ESMO 2026" in the headline

In the last 2 hours

ESMO 2026: BMS/SystImmune’s Iza-Bren Shows Benefit In NSCLC Scrip Pharma Intelligence 21:41

In the last 6 hours

ESMO 2026: Merck & Co Close To Sealing Its First Approval For Sac-TMT Scrip Pharma Intelligence 18:58

In the last 8 hours

Esmo 2026: Applying AI across tumor types BioWorld 16:07

Advertisement

Advertisement

ESMO 2026: AstraZeneca Set To Expand Imfinzi’s Bladder Cancer Reach With VOLGA Scrip Pharma Intelligence 16:04

Earlier Today

ESMO 2026: Akeso’s Ivonescimab Looks To Unseat Imfinzi In BTC Scrip Pharma Intelligence 14:52

ESMO 2026: Sacituzumab tirumotecan effective at decreasing recurrence of and death from endometrial cancer ecancer 14:43

Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at Esmo 2026 Business Wire (Press Release) 13:49

Iambic Presents Updated IAM1363 Clinical Data at Esmo 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers Business Wire (Press Release) 12:02

Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at Esmo 2026 Business Wire (Press Release) 11:10

ESMO 2026: Pfizer Oncology Chief On The ADC SV After Failing Phase III Scrip Pharma Intelligence 08:45

CStone Announces Major Clinical Validation Milestone for CS2009 at Esmo 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity PR Newswire (Press Release) 08:29

OncoHost Presents New Research Revealing Biological Drivers of Tki Sensitivity in Metastatic Renal Cell Carcinoma at Esmo 2026 PR Newswire (Press Release) 07:58

Esmo 2026 | Professors Jie Wang, Zhijie Wang and Jianchun Duan's Team Reports 95.2% Disease Control With LK101 Combination Maintenance Therapy in Advanced Nsclc PR Newswire (Press Release) 07:24

Antengene Presents Latest Clinical Results for Atg-022 and Atg-037 at Esmo 2026 PR Newswire (Press Release) 07:24

Advertisement

PureTech Presents Phase 1b Results for Lyt-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-Mds) and Acute Myeloid Leukemia (AML) at Esmo 2026 Business Wire (Press Release) 07:06

[ESMO 2026] BeOne's liver cancer drug could be a game changer, investigator says Korea Biomedical Review 06:14

[ESMO 2026] KDDF chief calls for targeted investment in globally competitive drug technologies Korea Biomedical Review 05:31

ESMO 2026: Sac-TMT Blazes Trail For Chemo-Free ADC/IO Regimen In 1L NSCLC Scrip Pharma Intelligence 05:12

[ESMO 2026] ABL Bio's ragistomig shows lower toxicity with 6-week dosing Korea Biomedical Review 05:06

Yesterday

ESMO 2026: AstraZeneca Set To Expand Infimzi’s Bladder Cancer Reach With VOLGA Scrip Pharma Intelligence 19:12 Sun, 25 Oct

ESMO 2026: Roche’s Big Divarasib Win Signals The End For KRAS G12C Rivals Scrip Pharma Intelligence 18:31 Sun, 25 Oct

ESMO 2026: New Targeted Therapy Improved Survival for Patients with KRAS-Mutated Lung Cancer Newswise (Press Release) 15:31 Sun, 25 Oct

ESMO 2026: UT MD Anderson highlights innovative approaches to monitor, prevent and treat cancer Newswise (Press Release) 14:19 Sun, 25 Oct

Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of Bot+Bal in Phase 2 Neoasis Study at Esmo 2026 Business Wire (Press Release) 11:04 Sun, 25 Oct

ESMO 2026: Cancer care coordination study presented ecancer 10:44 Sun, 25 Oct

ESMO 2026: Patients with a form of advanced lung cancer lived 56% longer without their disease progressing after... ecancer 09:43 Sun, 25 Oct

New data on Lilly's investigational treatment olomorasib at Esmo 2026 show durable first-line activity in Kras G12C-mutant non-small cell lung cancer PR Newswire (Press Release) 07:36 Sun, 25 Oct

Frontier Medicines Presents Promising Anti-Tumor Activity from Phase 1/2 prosper Trial of FMC-376 in a Highly Resistant Patient Population of Kras G12C-Mutant Nsclc at Esmo 2026 Business Wire (Press Release) 07:31 Sun, 25 Oct

Saturday

ESMO 2026: Ovation As Imdelltra/Imfinzi Cuts Risk Of Death By 58% in First-Line SCLC Scrip Pharma Intelligence 23:19 Sat, 24 Oct

ESMO 2026: GSK Makes The Case For Mo-Rez Scrip Pharma Intelligence 18:12 Sat, 24 Oct

ESMO 2026: Immunotherapy combo extends survival for patients with aggressive small cell lung cancer ecancer 17:56 Sat, 24 Oct

ESMO 2026: Adding abiraterone to ADT and docetaxel improves survival in metastatic prostate cancer ecancer 15:44 Sat, 24 Oct

ESMO 2026: Takeda Reaches First Summit With Claudin18.2 ADC Scrip Pharma Intelligence 15:39 Sat, 24 Oct

ESMO 2026: Scrip Pharma Intelligence 15:29 Sat, 24 Oct

ESMO 2026: Novel cancer immunotherapy drug generates promising clinical trial results ecancer 14:13 Sat, 24 Oct

ESMO 2026: Immunotherapy Combination Extends Survival in Advanced Endometrial Cancer Newswise (Press Release) 14:09 Sat, 24 Oct

Esmo 2026: Nubeqa® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence Business Wire (Press Release) 13:08 Sat, 24 Oct

Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at Esmo 2026 PR Newswire (Press Release) 12:02 Sat, 24 Oct

ESMO 2026: Perioperative apalutamide in high-risk localised or locally advanced prostate cancer substudy supports... ecancer 11:10 Sat, 24 Oct

ESMO 2026: Nearly one third of patients with advanced melanoma saw tumours disappear completely after receiving... ecancer 10:09 Sat, 24 Oct

Advertisement

Advertisement

News Now

Our Sites

News Now Nigeria

News Now România

News Now Italia

News Now Canada

News Now Australia

Work with us

Publisher Network

Dockside Online IDE

Legal

Subscription Terms

© Copyright 1997 - 2026 NewsNow Publishing Limited. All rights reserved.

Hot Topics Hot Topics
US US
Politics Politics
World World
Sports Sports
Business Business
Cryptocurrencies
Entertainment
Lifestyle Lifestyle
AI AI
Tech Tech
Science Science